Apply for Mavenclad (cladribine) Copay  Assistance, Copay Card & Financial Help

Mavenclad copay assistance and cladribine copay assistance programs help reduce or eliminate the out-of-pocket costs that patients pay for their medication. These programs are available through manufacturer-sponsored Mavenclad copay cards and independent patient assistance programs.

What QuickRx provides at no cost:

• Complete application assistance for copay cards and financial aid programs
• Insurance benefit verification and coverage analysis
• Continuous benefit monitoring to maintain your savings
• Home delivery coordination and prescription management
• Automatic refill reminders

Mavenclad savings programs available:

For commercially insured patients: Manufacturer copay cards can reduce your prescription costs, with many eligible patients paying significantly less out-of-pocket.

For Medicare patients: Independent foundation grant programs offer financial assistance to help cover medication expenses. These nonprofit programs are free to apply for, and QuickRx guides you through the entire process.

For uninsured or underinsured patients: Patient assistance programs may provide Mavenclad at no cost or significantly reduced prices based on household income and medical necessity.

Eligibility depends on your insurance type, medical diagnosis, and financial circumstances. Here’s how QuickRx makes enrollment simple:

Step 1: Reach out to QuickRx
Call (917) 830-2525 or toll-free (800) 496-6111, or complete our confidential online enrollment form.

Step 2: Insurance Review
Our team verifies your coverage and identifies which copay assistance programs match your insurance type.

Step 3: Qualification Assessment
We review eligibility requirements for each program—insurance type and diagnosis confirmation.

Step 4: Application Support
We handle all paperwork and follow up with each program to ensure timely approval.

General eligibility by insurance type:

Commercial Insurance: Most patients with employer-sponsored or marketplace insurance qualify for manufacturer copay cards.

Medicare Part D: Foundation grants available for eligible patients. QuickRx helps identify programs you may qualify for.

No Insurance: Patient assistance programs may provide medication to eligible patients. QuickRx helps you apply and navigate these programs.

Yes! While federal law prohibits manufacturer copay cards for Medicare Part D beneficiaries, QuickRx connects Medicare patients to independent charitable foundations that provide grants to cover Mavenclad costs.

How foundation grants work for Medicare patients:

Foundation Grant Programs:

• Independent nonprofit organizations offer financial assistance for Medicare patients
• Grants cover Part D deductibles, coinsurance, and copays
• Eligibility requirements vary by foundation
• Renewable grants every 3-12 months

Medicare Extra Help/Low-Income Subsidy:

• Federal program that reduces or eliminates Part D premiums, deductibles, and copays
• For beneficiaries who meet eligibility requirements
• QuickRx helps you understand eligibility and apply

QuickRx handles everything:

• Foundation grant applications and renewals
• Grant eligibility screening
• Documentation gathering
• Follow-up with foundations to ensure timely approval

Most Medicare patients we serve access foundation grants that cover their Mavenclad costs, making treatment affordable. Contact us at (917) 830-2525 to discuss your options.

Applying is simple. Complete the secure form on this page, and one of our patient navigators will contact you to guide you through the enrollment process. We handle the paperwork and coordinate with your healthcare provider to make the process as smooth as possible.

Here’s what to expect:

Step 1: Submit your information through our online form or call us directly.

Step 2: A dedicated patient navigator reviews your insurance and identifies all programs you may qualify for.

Step 3: We complete applications on your behalf and submit all required documentation.

Step 4: Once approved, we coordinate your prescription and arrange delivery.

The entire process typically takes just a few days, and you’ll know your exact out-of-pocket cost before your first order ships.

No. QuickRx Specialty Pharmacy offers completely free enrollment support for Mavenclad (cladribine) copay assistance programs. We don’t charge application fees or service charges—our mission is to help MS patients access affordable treatment.

What’s included at no cost:

• Complete application assistance for copay cards and financial aid programs
• Insurance benefit verification and coverage analysis
• Prior authorization support
• Continuous benefit monitoring to maintain your savings
• Home delivery coordination and prescription management
• Automatic refill reminders

QuickRx’s specialty pharmacy team works to eliminate financial barriers to your MS treatment, allowing you to focus on your health.

Mavenclad (cladribine) is an FDA-approved prescription medication used to treat relapsing forms of multiple sclerosis (MS) in adults, including relapsing-remitting MS (RRMS) and active secondary progressive MS (SPMS).

What is Multiple Sclerosis?

MS is a chronic autoimmune disease affecting the central nervous system. In MS, the immune system mistakenly attacks the protective myelin coating around nerve fibers, disrupting communication between the brain and the rest of the body. This can cause symptoms such as fatigue, numbness, difficulty walking, vision problems, and cognitive changes.

How Mavenclad (cladribine) helps MS patients:

Reduces Relapses: Clinical trials showed Mavenclad significantly reduced the annual relapse rate compared to placebo.

Slows Disability Progression: Studies demonstrated reduced risk of sustained disability progression in patients taking Mavenclad.

Targets Specific Immune Cells: Mavenclad works by selectively targeting certain B and T lymphocytes that are believed to play a role in the MS disease process.

Short-Course Treatment: Unlike daily medications, Mavenclad is taken for no more than 20 days total over two years.

FDA Approval: Mavenclad was approved by the FDA in March 2019 for adults with relapsing forms of MS.

Mavenclad (cladribine) is an oral tablet taken in two treatment courses over two years. This short-course dosing schedule means patients take the medication for no more than 20 days total.

Treatment Schedule:

Year 1 – First Treatment Course:

• Week 1: Take tablets daily for 4-5 consecutive days
• Week 2 (approximately 1 month later): Take tablets daily for 4-5 consecutive days

Year 2 – Second Treatment Course:

• Week 1: Take tablets daily for 4-5 consecutive days
• Week 2 (approximately 1 month later): Take tablets daily for 4-5 consecutive days

Dosing Information:

The number of tablets you take each day is calculated based on your body weight. The recommended cumulative dose is 3.5 mg/kg over the two-year treatment period.

Administration Tips:

• Take Mavenclad at the same time each day during treatment weeks
• Swallow tablets whole with water
• Can be taken with or without food
• Handle tablets with dry hands
• Take immediately after removing from blister pack

After Treatment:

Many patients do not require additional MS treatment for several years after completing the two treatment courses. Your neurologist will monitor your condition and discuss next steps.

Like all medications, Mavenclad (cladribine) can cause side effects. It’s important to discuss these with your healthcare provider. According to clinical information from MedlinePlus, here are potential side effects:

Very Common Side Effects (more than 1 in 10 people):

• Reduced white blood cell count (lymphopenia) – this is expected and monitored
• Upper respiratory infections (cold symptoms)
• Headache

Common Side Effects (up to 1 in 10 people):

• Oral herpes (cold sores)
• Shingles (herpes zoster)
• Back pain
• Joint pain
• Trouble sleeping

Serious Side Effects (Seek medical attention immediately):

• Signs of serious infection (fever, chills, persistent cough)
• Symptoms of liver problems (yellowing skin/eyes, dark urine)
• Severe allergic reactions
• Signs of cancer (unusual lumps, unexplained weight loss)

Required Monitoring:

Patients taking Mavenclad require regular monitoring by their healthcare provider:

• Blood tests before, during, and after treatment to monitor white blood cell counts
• Screening for infections including TB, hepatitis B and C
• Cancer screening as recommended by your healthcare provider
• Liver function tests

Mavenclad (cladribine) may not be appropriate for everyone. Your neurologist will evaluate your medical history to determine if Mavenclad is right for you.

Mavenclad should NOT be taken if you:

• Are currently pregnant or planning to become pregnant
• Are breastfeeding or plan to breastfeed
• Have an active infection, including TB, hepatitis B or C, or HIV
• Have active cancer or a history of certain cancers
• Have a weakened immune system due to other conditions or medications
• Are taking other medications that suppress the immune system

Important Considerations:

Pregnancy Prevention:

• Women must not be pregnant when starting Mavenclad
• Women must use effective contraception during treatment and for at least 6 months after the last dose
• Men must use contraception during treatment and for at least 6 months after the last dose

Vaccinations:

• Live or live-attenuated vaccines should not be given within 4-6 weeks before starting Mavenclad
• Discuss your vaccination status with your healthcare provider

Blood Tests Required:

• Blood tests are needed before starting to ensure your immune system and other health markers are adequate for treatment

Your healthcare team will review your complete medical history before prescribing Mavenclad.

Relapsing forms of multiple sclerosis include conditions where patients experience periods of new or worsening symptoms (relapses) followed by periods of recovery. Mavenclad is approved for these forms of MS.

Relapsing-Remitting MS (RRMS):

This is the most common form of MS, affecting about 85% of people initially diagnosed. It’s characterized by:

• Clearly defined relapses (flare-ups) of new or worsening neurological symptoms
• Periods of partial or complete recovery (remissions) between relapses
• No apparent disease progression between relapses

Active Secondary Progressive MS (SPMS):

Some people with RRMS eventually transition to secondary progressive MS, which involves:

• Gradual worsening of symptoms over time
• May or may not have occasional relapses
• “Active” SPMS means there is evidence of relapses or new MRI activity

Symptoms of Relapsing MS May Include:

• Fatigue
• Numbness or tingling
• Vision problems
• Difficulty walking or balance issues
• Muscle weakness or spasticity
• Cognitive changes
• Bladder or bowel problems

Mavenclad is designed to reduce the frequency of relapses and slow disability progression in patients with these relapsing forms of MS.

Mavenclad (cladribine) has demonstrated significant efficacy in clinical trials for relapsing forms of multiple sclerosis.

Key Clinical Trial Results (CLARITY Study):

Relapse Reduction:

• Mavenclad significantly reduced the annual relapse rate compared to placebo
• Many patients experienced fewer relapses over the study period

Disability Progression:

• Reduced risk of sustained disability progression compared to placebo
• Patients maintained function longer

MRI Results:

• Fewer new or enlarging brain lesions on MRI scans
• Reduced disease activity visible on imaging

Long-Term Benefits:

Studies following patients for up to 10+ years after treatment have shown:

• Many patients remained relapse-free without additional MS treatment
• Sustained benefits in preventing disability progression
• Lower rates of needing mobility aids compared to untreated patients

Treatment Durability:

One of Mavenclad’s unique features is that many patients do not need additional treatment for years after completing the two-year course. Your neurologist will monitor your condition and discuss whether additional treatment is needed.

Mavenclad (cladribine) has a unique approach compared to many other MS medications, both in how it works and how it’s taken.

Short-Course Dosing:

Unlike many MS treatments that require:

• Daily pills
• Weekly injections
• Monthly infusions
• Continuous treatment

Mavenclad is taken for no more than 20 days total over two years. After completing treatment, many patients don’t need additional MS therapy for several years.

Selective Immune Reconstitution:

Mavenclad works by:

• Selectively targeting certain B and T lymphocytes involved in MS
• Causing a temporary reduction in these specific immune cells
• Allowing the immune system to gradually rebuild (reconstitute) over time
• This rebuilt immune system is thought to be less likely to attack the nervous system

Non-Continuous Immunosuppression:

Because Mavenclad is taken for short periods, it only temporarily affects the immune system. This is different from some MS drugs that continuously suppress immune function for as long as you take them.

Oral Administration:

Mavenclad is a tablet you take by mouth—no injections or infusions required during your treatment weeks.

Blood tests and health monitoring are essential before, during, and after Mavenclad treatment to ensure safety.

Before Starting Treatment:

• Complete blood count (CBC) to check lymphocyte levels
• Screening for infections (TB, hepatitis B and C, HIV)
• Pregnancy test for women of childbearing potential
• Cancer screening as appropriate

During Treatment:

• Blood tests 2 and 6 months after starting each treatment course
• Monitoring for signs of infection
• Reporting any new or unusual symptoms to your healthcare provider

After Treatment:

• Blood tests until lymphocyte counts recover to normal levels
• Ongoing monitoring for delayed side effects
• Regular neurological assessments

Why Monitoring Matters:

Mavenclad temporarily reduces certain white blood cells (lymphocytes). Monitoring ensures:

• Your immune system recovers appropriately
• Any infections are caught and treated early
• Your overall health remains stable

Your healthcare provider will establish a monitoring schedule tailored to your needs. Following this schedule is important for safe and effective treatment.

Certain medications may interact with Mavenclad or increase the risk of side effects. Always inform your healthcare provider and pharmacist of all medications you’re taking.

Medications to Discuss with Your Doctor:

Other Immunosuppressants:

• Other MS disease-modifying therapies
• Medications that suppress the immune system
• These may increase infection risk when combined with Mavenclad

Live Vaccines:

• Live or live-attenuated vaccines should not be given during treatment
• Discuss vaccination timing with your healthcare provider

Certain Other Medications:

• Some HIV medications
• Medications that affect how drugs are processed in your body

Important Notes:

• Finish any live vaccine courses 4-6 weeks before starting Mavenclad
• Wait until your healthcare provider confirms it’s safe to receive live vaccines after treatment
• Non-live vaccines can generally be given during treatment

QuickRx provides comprehensive medication reviews to identify potential interactions. Our pharmacists work with your healthcare team to ensure all your medications work safely together.

Yes! QuickRx Specialty Pharmacy offers free nationwide home delivery of Mavenclad (cladribine) with appropriate packaging to ensure medication integrity.

What’s included with QuickRx home delivery:

Free Shipping:

• No delivery charges
• Secure packaging
• Signature required for security
• Tracking provided

Coordination with Treatment Schedule:

• Delivery timed to your treatment weeks
• You receive medication when you need it
• Reminder communications before each treatment course

Discreet Packaging:

• Plain packaging with no medication information visible
• Protects your privacy

Flexible Delivery:

• Choose delivery dates that work for your schedule
• Coordination with your healthcare provider’s treatment plan

Call (917) 830-2525 or (800) 496-6111 to set up home delivery with copay assistance enrollment.

Getting started with Mavenclad through QuickRx Specialty Pharmacy is easy. Our team handles the complex coordination so you can focus on your health.

Here’s how to begin:

Step 1: Contact Us

• Call (917) 830-2525 or toll-free (800) 496-6111
• Or complete the secure online form on this page

Step 2: We Verify Your Benefits

• Our team contacts your insurance to verify coverage
• We identify all copay assistance programs you may qualify for
• We provide a personalized cost estimate

Step 3: Copay Assistance Enrollment

• We complete applications for manufacturer copay cards, patient assistance programs, or foundation grants
• You provide basic information and documentation
• We handle all follow-up with programs

Step 4: Prescription Coordination

• We work with your neurologist to obtain your prescription
• Prior authorization handled if required
• All paperwork managed by our team

Step 5: Delivery

• Free home delivery to your door
• Timed to your treatment schedule
• Ongoing support throughout your treatment

Don’t let cost concerns delay your MS treatment. Contact QuickRx today and let us help you access the copay assistance you need.

References

1. National Institute of Neurological Disorders and Stroke. Multiple Sclerosis Information. Accessed December 2025.
2. Mayo Clinic. Multiple Sclerosis – Symptoms and Causes. Accessed December 2025.
3. Cleveland Clinic. Oral Cladribine (Mavenclad) for MS – Mellen Center Approach. Accessed December 2025.
4. MedlinePlus. Cladribine Drug Information. Accessed December 2025.
5. MedlinePlus. Multiple Sclerosis Overview. Accessed December 2025.
6. WebMD. Mavenclad Drug Information. Accessed December 2025.

Disclaimer: This page provides general information about Mavenclad (cladribine) copay assistance and is not medical advice. Patients should consult their healthcare provider for complete information about Mavenclad, including full prescribing information, potential side effects, and whether it’s appropriate for their condition. QuickRx Specialty Pharmacy is an independent pharmacy and is not affiliated with EMD Serono or the manufacturer of Mavenclad.

Last reviewed: December 2025